Xeris Biopharma Holdings, Inc.
A biopharmaceutical company developing and commercializing proprietary therapies targeting endocrine, neurological and gastrointestinal disorders. The company markets drugs for hypoglycemia, primary periodic paralysis and endogenous Cushing's syndrome, and is developing a potential treatment for the transient inhibition of gastrointestinal smooth muscle peristalsis. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Illinois |
Employees | 377 |
Founded | 2005 |
Financials | |
|---|---|
Market Capitalization | 349.14M |
Revenue | 171.36M |
Operating Income | -44.98M |
Operating Margin | -26.25% |
Net Income | -64.40M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4400 / 5373 |
Sector : Healthcare | 696 / 1144 |
Industry : Biotechnology | 314 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3247 / 5565 |
Sector : Healthcare | 496 / 1182 |
Industry : Biotechnology | 240 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4498 / 5436 |
Sector : Healthcare | 785 / 1164 |
Industry : Biotechnology | 381 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3135 / 5330 |
Sector : Healthcare | 359 / 1174 |
Industry : Biotechnology | 77 / 667 |